Although the precise mechanisms that underlie the anti-tumor efficacy of EphA2-based vaccines remain to be elucidated, our results demonstrate that the mEphA2-derived epitopes may represent important vaccine candidates for the development of clinical trials for the treatment of (both EphA2+ and EphA2-negative) cancers. Here, EPHA2 is linked to cancer.